INVAGEN PHARMS
GenericsINVAGEN PHARMS is a generic drug manufacturer focused on Neurology, Cardiovascular, Immunology. Key products include LEUPROLIDE ACETATE FOR DEPOT SUSPENSION.
INVAGEN PHARMS's Key Drugs
INVAGEN PHARMS's core commercial portfolio centers on LEUPROLIDE ACETATE FOR DEPOT SUSPENSION, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
INVAGEN PHARMS's Recent FDA Approvals
New NDA/BLA approvals for INVAGEN PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
INVAGEN PHARMS's Therapeutic Areas
INVAGEN PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
INVAGEN PHARMS's Top Competitors
INVAGEN PHARMS's closest competitors by therapeutic-area and drug-target overlap include Sanofi, Eli Lilly, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
INVAGEN PHARMS Pipeline Snapshot
Active clinical trials for INVAGEN PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LEUPROLIDE ACETATE FOR DEPOT SUSPENSION leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2005-04-20
- Latest
- 2026-05-15
- Applications
- 68